Casdin Capital LLC Purchases New Stake in ARS Pharmaceuticals, Inc. $SPRY

Casdin Capital LLC acquired a new position in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 1,600,000 shares of the company’s stock, valued at approximately $16,080,000. ARS Pharmaceuticals accounts for approximately 1.3% of Casdin Capital LLC’s portfolio, making the stock its 15th largest position. Casdin Capital LLC owned approximately 1.62% of ARS Pharmaceuticals as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of SPRY. CWM LLC boosted its position in shares of ARS Pharmaceuticals by 243.7% during the 3rd quarter. CWM LLC now owns 2,547 shares of the company’s stock worth $26,000 after purchasing an additional 1,806 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in shares of ARS Pharmaceuticals by 197.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,668 shares of the company’s stock valued at $67,000 after purchasing an additional 4,427 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of ARS Pharmaceuticals in the 3rd quarter valued at about $82,000. Osaic Holdings Inc. lifted its stake in shares of ARS Pharmaceuticals by 52.8% in the second quarter. Osaic Holdings Inc. now owns 5,215 shares of the company’s stock valued at $91,000 after purchasing an additional 1,803 shares during the period. Finally, CX Institutional acquired a new stake in shares of ARS Pharmaceuticals in the third quarter valued at about $92,000. Hedge funds and other institutional investors own 68.16% of the company’s stock.

ARS Pharmaceuticals Trading Up 1.8%

NASDAQ:SPRY opened at $8.39 on Friday. ARS Pharmaceuticals, Inc. has a 52-week low of $6.66 and a 52-week high of $18.90. The company has a quick ratio of 6.51, a current ratio of 7.28 and a debt-to-equity ratio of 1.47. The stock has a fifty day simple moving average of $9.89 and a 200-day simple moving average of $9.94. The company has a market capitalization of $833.13 million, a PE ratio of -4.79 and a beta of 0.78.

ARS Pharmaceuticals (NASDAQ:SPRY) last issued its quarterly earnings data on Monday, March 9th. The company reported ($0.42) EPS for the quarter, meeting analysts’ consensus estimates of ($0.42). ARS Pharmaceuticals had a negative net margin of 203.25% and a negative return on equity of 100.29%. The firm had revenue of $28.09 million for the quarter, compared to analysts’ expectations of $25.58 million. On average, equities research analysts expect that ARS Pharmaceuticals, Inc. will post -0.55 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SPRY has been the topic of several recent analyst reports. Zacks Research upgraded shares of ARS Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Leerink Partners set a $26.00 price target on shares of ARS Pharmaceuticals and gave the company an “outperform” rating in a research report on Tuesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of ARS Pharmaceuticals in a research note on Wednesday, January 21st. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, ARS Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $29.33.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.